-
Solomon Page Group LLC
Distance: 0.3 Mi260 Madison Ave Fl 3
10016-2401 New York -
Humanity Health
Distance: 0.7 Mi359 2nd Ave
10010-7436 New York -
ExL Pharma
Distance: 0.7 Mi555 8th Ave Rm 1703
10018 New York -
MYiDocUSA
Distance: 1.1 Mi167 Madison Ave 205 #1009
10016 New York -
Aortic International
Distance: 1.1 MiPO BOX 633
10031 New York
Description
Henry S. Friedman, M.D. ,is an internationally recognized neuro-oncologist with a career-long interest in the treatment of children and adults with brain and spinal cord tumors. As Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, he brings a unique team of specialists to the battle against brain tumors. The Brain Tumor Program at Duke was founded in 1937 and has the distinction of being one of the first in the United States; it also has the distinction of being one of the largest and most successful programs of its kind in the country.
Robert is a research scientist with 10 years of laboratory experience in Molecular Genetics and Medical Microbiology. Through a National Science Foundation training fellowship under the guidance of Dr. Dafna Bar-Sagi, Robert's research focused on signal transduction and cellular imaging of living cells in oncology. Robert has successfully parlayed his experience as a bench scientist into the role of incomparable educator of and advocate for patients as targeted therapies, molecular diagnostics, and gene expression profiling have become the centerpiece of cancer research and modern medicine.
Her interest in the creation of managed care organizations in the 1990's stemmed directly from her commitment to improving access to care for vulnerable populations. Between 1987 and 1992, Courtney worked with state and academic initiatives dedicated to improving clinical outcomes for low-income pregnant women and the chronically mentally ill population in Washington State. The success of these programs hinged on implementing patient-focused solutions and coordinated information sharing among local health and social service providers.
EmergingMed was founded in January 2000 after months of interviews with patients, advocates, caregivers and researchers who helped us understand the barriers, misperceptions, and logistical challenges associated with finding relevant clinical trials and making informed treatment decisions. The EmergingMed.com website was launched in October 2000.
EmergingMed enables trial sponsors to reach patients and physicians who are looking for clinical trial options. We provide a centralized and turn-key service that facilitates efficient and cost-effective trial recruitment. EmergingMed can operate its proprietary services on behalf of biopharmaceutical companies, which are particularly effective when integrated with other targeted communications to patients and physicians.